Efficacy of oral mexiletine in the prevention of exercise-induced ventricular ectopic activity.
The anti-arrhythmic effect of oral mexiletine on exercise-induced ventricular arrhythmia was studied in a double blind trial of 10 patients suffering from ventricular ectopic beats of different origins. There was a good reproducibility of the amount of ectopic ventricular activity between consecutive exercise tests when no active drug was given. Treatment for 1 week with mexiletine 600 mg daily resulted in a statistically significant reduction in ventricular ectopic beats, particularly during and after exercise; there were virtually no side-effects. The results suggest that mexiletine has considerable potential in the treatment of ventricular arrhythmias.
D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D005082:Physical Exertion; D011437:Propylamines / Q000627:therapeutic use*; D011674:Pulse / Q000187:drug effects
D011437:Propylamines; D008801:Mexiletine